Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2020, vol. 29, nr 4, April, p. 453–458

doi: 10.17219/acem/118126

Publication type: original article

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The relation of endocan and galectin-3 with ST-segment resolution in patients with ST-segment elevation myocardial infarction

Yaşar Turan1,A,B,C,D,E,F, Vahit Demir1,A,B,C,D,E,F

1 Department of Cardiology, Faculty of Medicine, Bozok University, Yozgat, Turkey


Background. ST-segment elevation myocardial infarction (STEMI) remains a leading cause of morbidity and mortality around the world. In patients with STEMI undergoing primary percutaneous coronary intervention (PPCI), electrocardiographic measures of ST-segment resolution (STR) may give information about the myocardial perfusion and poor prognosis.
Objectives. To investigate the relation of endocan and galectin-3 levels with STR in STEMI patients.
Material and Methods. In this cross-sectional study, 98 consecutive patients undergoing PPCI for STEMI were enrolled. Synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) scores were recorded. Electrocardiograms were assessed at baseline and 60 min after PPCI. According to STR levels, patients undergoing PPCI (n = 98) were divided into complete STR group (≥70%, n = 53) and incomplete STR group (<70%, n = 45).
Results. Serum glucose, total cholesterol, low-density lipoprotein cholesterol, SYNTAX score, endocan and galectin-3 levels were significantly higher and ejection fraction was significantly lower in the incomplete STR (<70%) group (p < 0.05 for all). Body mass index (BMI) (p = 0.046) and galectin-3 (p = 0.037) were independently associated with the SYNTAX score. Endocan (p = 0.044) and galectin-3 (p = 0.017) were independent predictors of incomplete STR.
Conclusion. In patients with STEMI, the levels of endocan and galectin-3 may be helpful in identifying patients with a higher risk of insufficient myocardial perfusion and worse clinical outcome after PPCI.

Key words

ST-segment elevation myocardial infarction, galectin-3, endocan, ST-segment resolution

References (28)

  1. Davies MJ. The pathophysiology of acute coronary syndromes. Heart. 2000;83:361–366.
  2. Carville S, Harker M, Henderson R, Gray H. Acute management of myocardial infarction with ST-segment elevation: Summary of NICE guidance. BMJ. 2013;347:f4006.
  3. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation. 1996;93:1993–1999.
  4. Unikas R, Budrys P. Association between clinical parameters and ST-segment resolution after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Medicina (Kaunas). 2016;52:156–162.
  5. McLaughlin MG, Stone GW, Aymong E, et al. Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. J Am Coll Cardiol. 2004;44:1215–1223.
  6. Ozaki K, Toshikuni N, George J, et al. Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma. J Cancer. 2014;5:221–230.
  7. Balta S, Mikhailidis DP, Demirkol S, et al. Endocan – a novel inflammatory indicator in newly diagnosed patients with hypertension: A pilot study. Angiology. 2014;65:773–777.
  8. Kundi H, Balun A, Cicekcioglu H, et al. Admission endocan level may be a useful predictor for in-hospital mortality and coronary severity index in patients with st-segment elevation myocardial infarction. Angiology. 2017;68:46–51.
  9. Martinez-Martinez E, Calvier L, Fernandez-Celis A, et al. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension. 2015;66:767–775.
  10. Maiolino G, Rossitto G, Pedon L, et al. Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. Arterioscler Thromb Vasc Biol.2015;35:725–732.
  11. George M, Shanmugam E, Srivatsan V, et al. Value of pentraxin-3 and galectin-3 in acute coronary syndrome: A short-term prospective cohort study. Ther Adv Cardiovasc Dis. 2015;9:275–284.
  12. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018;72:2231–2264.
  13. Ong AT, Serruys PW, Mohr FW, et al. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: Design, rationale, and run-in phase. Am Heart J. 2006;151:1194–1204.
  14. Qiu CR, Fu Q, Sui J, et al. Serum endothelial cell-specific molecule 1 (Endocan) levels in patients with acute myocardial infarction and its clinical significance. Angiology. 2017;68:354–359.
  15. Gucuk Ipek E, Akin Suljevic S, Kafes H, et al. Evaluation of galectin-3 levels in acute coronary syndrome. Ann Cardiol Angeiol (Paris). 2016;65:26–30.
  16. Lee W, Ku SK, Kim SW, Bae JS. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol 2014;229:620–630.
  17. Jaipersad AS, Lip GY, Silverman S, Shantsila E. The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol. 2014;63:1–11.
  18. Ozturk D, Celik O, Satilmis S, et al. Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus. Coron Artery Dis. 2015;26:396–401.
  19. Zhang B, Pei C, Zhang Y, Sun Y, Meng S. High resting heart rate and high BMI predicted severe coronary atherosclerosis burden in patients with stable angina pectoris by SYNTAX Score. Angiology. 2018;69:380–386.
  20. Winter MP, Wiesbauer F, Alimohammadi A, et al. Soluble galectin-3 is associated with premature myocardial infarction. Eur J Clin Invest. 2016;46:386–391.
  21. Daiber A, Xia N, Steven S, et al. New therapeutic implications of endothelial nitric oxide synthase (eNOS) function/dysfunction in cardiovascular disease. Int J Mol Sci. 2019;20:187.
  22. Zeller M, Korandji C, Guilland JC, et al. Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2008;28:954–960.
  23. Galiuto L. Optimal therapeutic strategies in the setting of post-infarct no reflow: The need for a pathogenetic classification. Heart. 2004;90:123–125.
  24. Salvagno GL, Pavan C. Prognostic biomarkers in acute coronary syndrome. Ann Transl Med. 2016;4:258.
  25. Tsai TH, Sung PH, Chang LT, et al. Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J Atheroscler Thromb. 2012;19:1073–1082.
  26. Ziaee M, Mashayekhi S, Ghaffari S, Mahmoudi J, Sarbakhsh P, ­Garjani A. Predictive value of endocan based on TIMI risk score on major adverse cardiovascular events after acute coronary syndrome. Angiology. 2018:3319718815241.
  27. Ye MF, Zhao ZW, Luo YK, Dong XF, Yan YM. Elevated endocan concentration is associated with coronary slow flow. Scand J Clin Lab Invest. 2016;76:345–348.
  28. Qiu C, Sui J, Zhang Q, Wei P, Wang P, Fu Q. Relationship of endothelial cell-specific molecule 1 level in stress hyperglycemia patients with acute ST-segment elevation myocardial infarction: A pilot study. Angiology. 2016;67:829–834.